Explore the vast range of titles available.

Aims: Cytomegalovirus (CMV) colitis in individuals with inflammatory bowel disease (IBD) is a serious condition. The present study evaluated the prevalence and outcome of IBD-CMV colitis among patients with CMV disease. Methods: We performed a retrospective study to evaluate the patients with IBD and CMV colitis between January 1, 2017, and December 31, 2022. We identified IBD-CMV colitis based on the presence of CMV in tissue or a polymerase chain reaction (PCR) result of >1000 copies/mL with no other clinical explanations. The frequency of IBD-CMV colitis, relapse rate, requirement of surgical interventions, and associated mortality were assessed. Results: Out of 163 patients with CMV disease screened, 28 (17.2%) were diagnosed with CMV colitis and IBD [median age: 54 (19-67) years, male: 77%]. The frequency of ulcerative colitis and Crohn's disease was 93% and 7%, respectively. Most CMV PCR assays (97%) were performed using serum, whereas the remaining tests were performed using serum and tissue samples. CMV was not detected via immunohistochemistry or hematoxylin-eosin staining in any patient. Antiviral treatment was initiated in 74% of the patients and lasted a median of 20 days (6-32 days). No surgical interventions or disease-related deaths were identified. Conclusions: This electronic medical records study showed that IBD-CMV colitis was a rare disease among patients with CMV disease and generally followed a favorable course. Keywords: Inflammatory bowel disease, cytomegalovirus, diagnosis, treatment, prognosis

Introduction: Linezolid is a synthetic antimicrobial agent with a broad spectrum of activity against virtually all Gram-positive bacteria. Although linezolid is generally well tolerated, the prolonged use of linezolid can lead to myelosuppression, including neutropenia, thrombocytopenia, and anemia. The aim of this study was investigating the risk factors for thrombocytopenia in patients who received linezolid therapy. Methodology: This retrospective study was performed on patients who received linezolid therapy between July 2007 and December 2017. Thrombocytopenia was defined as either a platelets count of < 100×109/L or a 25% reduction from the baseline platelet count. Results: A total of 371 patients, (198 (53%) male and 173(47%) female were included into the study. Mean duration of therapy was 12.81 ± 5.19 days. Linezolid-induced thrombocytopenia was detected in a total of 111 patients. Using the univariate analysis advanced sex, serum urea concentration, baseline platelet level and low eGFR value were found to be risk factors for linezolid associated thrombocytopenia (p < 0.05). According to a multivariate analysis, patients undergoing carbapenem treatment combination therapy (p = 0.003) and with a baseline platelet level of < 200×109/L (p = 0.00) were found to have a high risk of developing thrombocytopenia. Conclusions: Several factors may influence of linezolid associated thrombocytopenia. Platelet count should be monitored during therapy and thrombocytopenia should be kept in mind in patients with baseline platelet level of < 200×109/L, low eGFR, linezolid-carbapenem combination therapy.

Extranodal natural killer/T-cell lymphoma (ENKTL) is an Epstein-Barr virus-associated, rapidly spreading lymphoproliferative disorder with a poor prognosis. Although it usually manifests with nasal involvement, different clinical and histopathological features can be detected. In nasal form, it may be confused with mucormycosis. Identifying the appropriate biopsy site is crucial for an accurate ENKTL-nasal type diagnosis, and positron emission tomography/computed tomography (PET/CT) can facilitate this. In this paper, we share the case of a 73-year-old male who presented with nasal and skin involvement, and was diagnosed with an unfavourable prognosis using PET/CT-guided biopsy. Unfortunately, the initial biopsies were inconclusive and led to an unnecessary antimicrobial treatment. Combining fluorodeoxyglucose PET/CT images allowed us to pinpoint the biopsy location and assess the depth of tissue infiltration, resulting in a successful biopsy even in this rare case.

Knowing risk factors for colistin resistance is important since colistin is the only remaining choice for the treatment of infections caused by multi-drug resistant microorganisms. Evaluate risk factors associated with infection by colistin-resistant microorganisms. Retrospective study. Tertiary healthcare centers. An e-mail including the title and purpose of the study was sent to 1500 infec.tious disease specialists via a scientific and social web portal named \"infeksiyon dunyasi (infection world)\". Demographic and clinical data was requested from respondents. Colistin-resistance. Eighteen infectious disease specialists from twelve tertiary care centers responded to the invitation data was collected on 165 patients, 56 cases (39.9%) and 109 (66.0%) age- and sex-matched controls. The colistin-resistant microorganisms isolated from cases were 29 Acinetobacter baumannii (51.8%), 18 Pseudomonas aeruginosa (32.1%) and 9 Klebsiella spp. Colistin, carbapenem, and quinolone use in the last three months were risk factors for colistin resistance in the univariate analysis. Previous quinolone use in the last three months (P=.003; RR:3.2; 95% Ci:1.5-6,7) and previous colistin use in the last three months (P=.001; RR: 3.6; 95% CI: 1.63-7.99) were significant risk factors in the multivariate analysis. Clinicians should limit the use of quinolones and remain aware of the possibility of resistance developing during colistin use. The lack of a heteroresistance analysis on the isolates. no data on use of a loading dose or the use of colistin in combination.

Aim: Tigecycline has been approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections, skin and soft tissue infections and community-acquired pneumonia. In our study, we examined the efficacy of tigecycline in clinical practice and reported real life data from our hospital over a period of five years. Methods: The study was conducted between 2008 and 2013 on patients who received tigecycline for longer than 48 hours in Ankara Training and Research Hospital. Clinical success was defined as clinical recovery and microbiological cure in patients who used tigecycline. Any reason for discontinuation of tigecycline treatment was considered a clinical failure. Results: In our hospital, 320 patients were administered tigecycline between 2008 and 2013. Tigecycline was mainly used for pneumonia and skin and soft tissue infections. Tigecycline was used as monotherapy in 174 patients (54.1%). The most frequently isolated agent in tigecycline-treated patients was Acinetobacter baumannii (43.4%) followed by Enterococcus (6.9%). A change in treatment was not considered necessary in 243 (75.9%) patients who received tigecycline, while it was changed in 77 patients (24.1%). Conclusion: In conclusion, the use of tigecycline can be an effective treatment choice, either as monotherapy or as a combination antibiotic therapy.

Introduction: Infections related to the use of invasive instruments leads to the risk of treatment difficulties, prolonged hospitalization, increased health care costs, and increased mortality and morbidity rates. The present study examines the results of an infection surveillance study that showed an increased incidence of infections related to the use of invasive instruments in the cardiovascular surgery intensive care unit of the Ankara Training and Research Hospital and mitigating measures were taken following the surveillance program. Methodology: Compared with previous surveillance data, an increase was observed in the incidence of infections related to the use of invasive instruments in cardiovascular surgery intensive care unit (CVS-ICU) during the first six months of 2014. A research team was formed comprising one infectious diseases and microbiology specialist, one cardiovascular surgeon, and two infection-control nurses. Patient data was collected. The compliance of the surgeons, nurses, and other health care professionals to the infection control measures was evaluated. Results: The rate of ventilator-associated pneumonia was 8.20% and the rate of catheter-associated urinary tract infection was 4.47% in the CVS-ICU. There were missing or inadvertent practices regarding antibiotic prophylaxis, asepsis and antisepsis and isolation measures in patient preparation and patient care before and after the operations. The rate of inappropriate antibiotic as prolonged use was 72%. Conclusions: It is one of the basic tasks to take appropriate measures to prevent outbreaks of hospital infections. It is possible to prevent an outbreak of hospital infections only by the accurate analysis of data and establishing strict infection control procedures.